Cellectis S.A. (CLLS) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($141.3 million vs $125.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | RNA |
|---|---|---|
| Share price | $1.25 | $8.26 |
| Market cap | $125.90M | $141.29M |
| 1-day change | -6.72% | +4.16% |
| YTD return | -74.17% | — |
| 1-year return | -70.93% | — |
| 5-year return | -88.46% | — |
| EPS (TTM) | $-0.64 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $16.77 |
| 52-week low | $1.22 | $7.63 |
| Distance from 52-week high | -77.19% | -50.75% |
| Analyst consensus | none | none |
| Avg. price target upside | +326.40% | +202.66% |
| Average volume | 80.14K | 259.35K |
| Shares outstanding | 72.72M | 17.11M |
| Employees | 224 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
CLLS vs RNA FAQ
Which is bigger, Cellectis S.A. or Atrium Therapeutics?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $141.29M compared with $125.90M for Cellectis S.A. (CLLS).
Are Cellectis S.A. and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.